Glyclopyramide

Glyclopyramide

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-chloro-N-[(pyrrolidin-1-ylamino)carbonyl]benzenesulfonamide
CAS Number	631-27-6^N
PubChem CID	71793
ChemSpider	64820^N
UNII	KE474IKG1W
KEGG	D01799^Y
ChEMBL	ChEMBL2105083^N
CompTox Dashboard (EPA)	DTXSID2048822
Chemical and physical data
Formula	C11H14ClN3O3S
Molar mass	303.76 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CCN(C1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
InChI InChI=1S/C11H14ClN3O3S/c12-9-3-5-10(6-4-9)19(17,18)14-11(16)13-15-7-1-2-8-15/h3-6H,1-2,7-8H2,(H2,13,14,16)^N Key:HNSCCNJWTJUGNQ-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.

It is classified as second generation.^[1]

References

1. Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese). 38 (1): 11–27. PMID 14570054.

External links

• DEAMELIN·S Tablets 250 mg Archived 2018-11-01 at the Wayback Machine